Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05685641
Other study ID # 181250
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 1, 2023
Est. completion date September 30, 2024

Study information

Verified date January 2023
Source National Institute of Respiratory Diseases, Mexico
Contact Victor Ahumada Topete, MD
Phone 55 5487 1700
Email victor.ahumada@uehi.mx
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In Mexico City, the main cause of mortality among people living with HIV (PLHIV) continues to be opportunistic infections (OIs). Early detection of OIs allows their timely treatment and improves their prognosis. The use of rapid diagnostic tests (RDT) based on antigens of the most frequent causative agents of OIs allows adequate screening of these patients and facilitates decision making at the point of care. Unfortunately, these studies are not widely available in the different PLHIV care centers in the CDMX. We will conduct an open-label, non-inferiority uncontrolled clinical trial to investigate the diagnostic performance of urinary lipoarabinomannan, urinary Histoplasma antigen and serum Cryptococcus antigen in patients presenting for care with advanced HIV in CDMX, supported by rapid cluster of differentiation 4 (CD4) testing with lateral flow technology. Four referral hospitals will participate over 12 months. All patients with diagnosed HIV disease and suspected advanced disease presenting for care at participating centers will be included in the study. An inventory of approximately 1000 RDT will be obtained and distributed among the participating sites. A study coordinator will be hired and will visit each site once a week to collect the study variables and follow up on the included patients. The primary outcome of the study will be the percentage of patients with advanced disease who present with diagnoses made by RDT compared to historical controls of patients diagnosed with OI in 2022 at participating centers by conventional methods. Secondary outcomes will be time to initiation of antiretroviral therapy (ART), time to initiation of OI treatment, and 30-day mortality after HIV diagnosis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 211
Est. completion date September 30, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Positive ELISA test or positive viral load for HIV. - Patients with suspected or confirmed advanced HIV disease defined as follows: - Confirmed: asymptomatic patients with CD4 count less than 200 cells/ml within 3 months of study inclusion or confirmed diagnosis of an AIDS-defining opportunistic illness within the last 3 months. - Suspected: patients who, irrespective of CD4 count, present any symptoms suggestive of systemic infection that, at the discretion of the treating physicians, produce suspicion of an AIDS-defining opportunistic disease (e.g., fever, productive cough, diaphragmatic diapers, etc.). Fever, productive cough, nocturnal diaphoresis, altered mental status, headache, lymphadenopathy, dermatological lesions) or that meet criteria for HIV wasting syndrome (loss of 10% of baseline weight plus the presence of chronic diarrhea or chronic weakness and an episode of fever in the last 30 days). - Patients without effective antiretroviral therapy defined as not having received antiretroviral treatment in the last 3 months or in virologic failure (2 consecutive viral loads with more than 1000 copies/ml). Exclusion Criteria: - Patients with a viral load of less than 1000 copies/ml. - Patients presenting for care having started treatment for systemic mycoses (amphotericin B or azoles) and tuberculosis.

Study Design


Intervention

Diagnostic Test:
Histoplasma Urine Antigen Lateral Flow Antigen test
Lateral Flow Antigen test for urine samples to detect Histoplasma capsulatum disseminated disease
Cryptococcal Lateral Flow Antigen test
Lateral Flow Antigen test for serum or cerebrospinal fluid samples to detect Cryptococcus sp meningitis or disseminated disease
Tuberculosis-lipoarabinomannan Lateral Flow Antigen test
Lateral Flow Antigen test for serum samples to detect Mycobacterium tuberculosus disease

Locations

Country Name City State
Mexico General Hospital Dr. Manuel Gea Gonzalez Mexico City
Mexico National Center of Nutrition and Medical Sciences Mexico City
Mexico National Institute of Cancerology Mexico City
Mexico National Institute of Respiratory Diseases Mexico City

Sponsors (4)

Lead Sponsor Collaborator
National Institute of Respiratory Diseases, Mexico Hospital General Dr. Manuel Gea González, National Institute of Cancerology, National Institute of Medical Sciences and Nutrition, Salvador Zubiran

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time until opportunistic infection treatment initiation Amount of time in days from the diagnosis of the opportunistic infection until the initiation of the specific treatment for the detected infection 30 days
Secondary AIDS-related mortality at 30 days If a patient has died due to AIDS-related causes 30 days
Secondary AIDS-related mortality at 90 days If a patient has died due to AIDS-related causes 90 days
Secondary Monthly incidence of histoplasmosis, cryptococcosis and tuberculosis The amount of diagnosed cases of histoplasmosis, cryptococcosis and tuberculosis per amount of advanced HIV-patients seen every month in the study sites Through study completion, an average of 1 year
Secondary Time until antiretroviral treatment initiation Days passed from a patient's HIV diagnosis until he is given antiretroviral treatment for the first time 30 days
See also
  Status Clinical Trial Phase
Completed NCT01968551 - Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults Phase 3
Completed NCT02929069 - A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk N/A
Recruiting NCT02392884 - HIV Medication Adherence in Underserved Populations N/A
Completed NCT02583464 - Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg. Phase 1
Completed NCT02264509 - Peripheral Arterial Insufficiency Associated With HIV/AIDS N/A
Completed NCT01440569 - Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults Phase 3
Completed NCT00551330 - Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED) Phase 2
Completed NCT00381212 - A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent. Phase 1/Phase 2
Completed NCT00097006 - Retrovirus Epidemiology Donor Study-II (REDS-II) N/A
Completed NCT00001409 - Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications Phase 1
Completed NCT00000590 - Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Phase 3
Completed NCT00000587 - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection Phase 2
Completed NCT00005273 - Pulmonary Complications of HIV Infection Study (PACS) N/A
Completed NCT00005303 - Effectiveness of AIDS Antibody Screening N/A
Completed NCT00005301 - Transfusion Safety Study (TSS) N/A
Completed NCT00001650 - Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients N/A
Withdrawn NCT00243568 - Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285 Phase 3
Recruiting NCT05031819 - Managing Hypertension Among People Living With HIV N/A
Completed NCT00394004 - Decision-Making of Hispanics and African-Americans With HIV/AIDS Participating in Clinical Trials N/A
Completed NCT01967940 - Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults Phase 3